- Email: [email protected]
Information for category 1 CME credit
T HE J OURNAL OF
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.mosby.com/jaci. The accompanying tests may only be submitted online at www.mosby.com/jaci. Fax or other copies will not be accepted. Date of Original Release: April 2004. Credit may be obtained for these courses until March 31, 2005. Copyright Statement: Copyright Ó 2004-2005. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for up to 1.0 hour in category I credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he or she actually spent in the educational activities.
CME article
CME article
‘‘Clinical and laboratory evaluation of complement deficiency’’
‘‘Successes and risks of gene therapy in primary immunodeficiencies’’
(page 585)
(page 595)
List of Design Committee Members: Authors: Lenna Wen, MD, John P. Atkinson, MD, and Patricia Giclas, PhD Activity Objectives 1. To know the differences between the pathways of complement activation and their control mechanisms. 2. To understand the role that complement activation products play in the pathophysiology of certain disease states. 3. To be able to distinguish between low complement resulting from a genetic deficiency and an ongoing activation process. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Lenna Wen, John P. Atkinson, and Patricia Giclas have no significant relationships to disclose.
List of Design Committee Members: Authors: Javier Chinen, MD, PhD, and Jennifer M. Puck, MD Activity Objectives 1. To discuss the actual and theoretical advantages of gene therapy in primary immunodeficiencies. 2. To review the progress of gene therapy as a therapeutic option for primary immunodeficiencies. 3. To understand the risk of insertional mutagenesis and leukemia in patients receiving hematopoietic stem cells transduced with a retroviral vector. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Javier Chinen and Jennifer M. Puck have no significant relationships to disclose.
40A April 2004
J ALLERGY CLIN IMMUNOL
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.mosby.com/jaci. The accompanying tests may only be submitted online at www.mosby.com/jaci. Fax or other copies will not be accepted. Date of Original Release: April 2004. Credit may be obtained for these courses until March 31, 2005. Copyright Statement: Copyright Ó 2004-2005. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for up to 1.0 hour in category I credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he or she actually spent in the educational activities.
CME article
CME article
‘‘Clinical and laboratory evaluation of complement deficiency’’
‘‘Successes and risks of gene therapy in primary immunodeficiencies’’
(page 585)
(page 595)
List of Design Committee Members: Authors: Lenna Wen, MD, John P. Atkinson, MD, and Patricia Giclas, PhD Activity Objectives 1. To know the differences between the pathways of complement activation and their control mechanisms. 2. To understand the role that complement activation products play in the pathophysiology of certain disease states. 3. To be able to distinguish between low complement resulting from a genetic deficiency and an ongoing activation process. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Lenna Wen, John P. Atkinson, and Patricia Giclas have no significant relationships to disclose.
List of Design Committee Members: Authors: Javier Chinen, MD, PhD, and Jennifer M. Puck, MD Activity Objectives 1. To discuss the actual and theoretical advantages of gene therapy in primary immunodeficiencies. 2. To review the progress of gene therapy as a therapeutic option for primary immunodeficiencies. 3. To understand the risk of insertional mutagenesis and leukemia in patients receiving hematopoietic stem cells transduced with a retroviral vector. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Javier Chinen and Jennifer M. Puck have no significant relationships to disclose.
40A April 2004
J ALLERGY CLIN IMMUNOL